54 related articles for article (PubMed ID: 9384701)
1. Gene therapy with modified tumor cells enables T-cell activation by stimulating pathways required for signal transduction.
Salvadori S; Zier K
Cytokines Mol Ther; 1996 Sep; 2(3):171-5. PubMed ID: 9384701
[TBL] [Abstract][Full Text] [Related]
2. Abnormal signal transduction by T cells of mice with parental tumors is not seen in mice bearing IL-2-secreting tumors.
Salvadori S; Gansbacher B; Pizzimenti AM; Zier KS
J Immunol; 1994 Dec; 153(11):5176-82. PubMed ID: 7963575
[TBL] [Abstract][Full Text] [Related]
3. Molecular basis of T cell dysfunction in cancer is influenced by the paracrine secretion of tumor-derived IL-2.
Salvadori S; Zier K
J Immunol; 1996 Apr; 156(8):2927-32. PubMed ID: 8609413
[TBL] [Abstract][Full Text] [Related]
4. Functional defects are associated with abnormal signal transduction in T cells of mice inoculated with parental but not IL-2 secreting tumor cells.
Salvadori S; Gansbacher B; Zier K
Cancer Gene Ther; 1994 Sep; 1(3):165-70. PubMed ID: 7542552
[TBL] [Abstract][Full Text] [Related]
5. The glycosylphosphatidylinositol-anchored CD59 protein stimulates both T cell receptor zeta/ZAP-70-dependent and -independent signaling pathways in T cells.
Deckert M; Ticchioni M; Mari B; Mary D; Bernard A
Eur J Immunol; 1995 Jul; 25(7):1815-22. PubMed ID: 7542590
[TBL] [Abstract][Full Text] [Related]
6. Lack of correlation between rejection of tumor cells co-expressing interleukin-2 and B7.1 and vaccine efficiency.
Cayeux S; Richter G; Becker C; Beck C; Aicher A; Pezzutto A; Dörken B; Blankenstein T
Eur J Immunol; 1997 Jul; 27(7):1657-62. PubMed ID: 9247574
[TBL] [Abstract][Full Text] [Related]
7. Defective TCR-mediated signaling in anergic T cells.
Migita K; Eguchi K; Kawabe Y; Tsukada T; Ichinose Y; Nagataki S; Ochi A
J Immunol; 1995 Dec; 155(11):5083-7. PubMed ID: 7594516
[TBL] [Abstract][Full Text] [Related]
8. Transferrin receptor induces tyrosine phosphorylation in T cells and is physically associated with the TCR zeta-chain.
Salmerón A; Borroto A; Fresno M; Crumpton MJ; Ley SC; Alarcón B
J Immunol; 1995 Feb; 154(4):1675-83. PubMed ID: 7836751
[TBL] [Abstract][Full Text] [Related]
9. Multiple signal transduction pathways activated through the T cell receptor for antigen.
Siegel JN; Egerton M; Phillips AF; Samelson LE
Semin Immunol; 1991 Sep; 3(5):325-34. PubMed ID: 1724737
[TBL] [Abstract][Full Text] [Related]
10. Activation of T cells via CD55: recruitment of early components of the CD3-TCR pathway is required for IL-2 secretion.
Tosello AC; Mary F; Amiot M; Bernard A; Mary D
J Inflamm; 1998; 48(1):13-27. PubMed ID: 9368189
[TBL] [Abstract][Full Text] [Related]
11. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
[TBL] [Abstract][Full Text] [Related]
12. Vaccination with IL-2-secreting tumor cells stimulates the generation of IL-2-responsive T cells and prevents the development of unresponsiveness.
Zier KS; Salvadori S; Cronin KC; Gansbacher B
Cancer Gene Ther; 1994 Mar; 1(1):43-50. PubMed ID: 7621237
[TBL] [Abstract][Full Text] [Related]
13. Adoptive immunotherapy with tumor-specific T lymphocytes generated from cytokine gene-modified tumor-primed lymph node cells.
Ohno K; Yoshizawa H; Tsukada H; Takeda T; Yamaguchi Y; Ichikawa K; Maruyama Y; Suzuki Y; Suzuki E; Arakawa M
J Immunol; 1996 May; 156(10):3875-81. PubMed ID: 8621926
[TBL] [Abstract][Full Text] [Related]
14. T cells infiltrating non-Hodgkin's B cell lymphomas show altered tyrosine phosphorylation pattern even though T cell receptor/CD3-associated kinases are present.
Wang Q; Stanley J; Kudoh S; Myles J; Kolenko V; Yi T; Tubbs R; Bukowski R; Finke J
J Immunol; 1995 Aug; 155(3):1382-92. PubMed ID: 7636203
[TBL] [Abstract][Full Text] [Related]
15. Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin 2 therapy.
Rabinowich H; Banks M; Reichert TE; Logan TF; Kirkwood JM; Whiteside TL
Clin Cancer Res; 1996 Aug; 2(8):1263-74. PubMed ID: 9816296
[TBL] [Abstract][Full Text] [Related]
16. Differential loss of T cell signaling molecules in metastatic melanoma patients' T lymphocyte subsets expressing distinct TCR variable regions.
Maccalli C; Pisarra P; Vegetti C; Sensi M; Parmiani G; Anichini A
J Immunol; 1999 Dec; 163(12):6912-23. PubMed ID: 10586094
[TBL] [Abstract][Full Text] [Related]
17. Recruitment of Sprouty1 to immune synapse regulates T cell receptor signaling.
Lee JS; Lee JE; Oh YM; Park JB; Choi H; Choi CY; Kim IH; Lee SH; Choi K
J Immunol; 2009 Dec; 183(11):7178-86. PubMed ID: 19915061
[TBL] [Abstract][Full Text] [Related]
18. Murine TRAIL (TNF-related apoptosis inducing ligand) expression induced by T cell activation is blocked by rapamycin, cyclosporin A, and inhibitors of phosphatidylinositol 3-kinase, protein kinase C, and protein tyrosine kinases: evidence for TRAIL induction via the T cell receptor signaling pathway.
Musgrave BL; Phu T; Butler JJ; Makrigiannis AP; Hoskin DW
Exp Cell Res; 1999 Oct; 252(1):96-103. PubMed ID: 10502402
[TBL] [Abstract][Full Text] [Related]
19. Characterization of signal transduction through the TCR-zeta chain following T cell stimulation with analogue peptides of type II collagen 260-267.
Tang B; Myers LK; Rosloniec EF; Whittington KB; Stuart JM; Kang AH
J Immunol; 1998 Apr; 160(7):3135-42. PubMed ID: 9531268
[TBL] [Abstract][Full Text] [Related]
20. Tyrosine phosphorylation is an obligatory event in IL-2 secretion.
Stanley JB; Gorczynski R; Huang CK; Love J; Mills GB
J Immunol; 1990 Oct; 145(7):2189-98. PubMed ID: 1697878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
